Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Neutral 64.6%

Neg 0% Neu 64.6% Pos 0%

Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.